Prospective Multi-centre Study of Prognostic Factors in Castration Resistant PROState Cancer Treated With Enzalutamide

Trial Profile

Prospective Multi-centre Study of Prognostic Factors in Castration Resistant PROState Cancer Treated With Enzalutamide

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms PROSENZA
  • Most Recent Events

    • 12 Sep 2017 According to an abstract presented at the 42nd European Society for Medical Oncology Congress, 48 centres are now recruiting and 54 patients have been included in this trial.
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top